Thyroid Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People diagnosed with radioiodine-refractory differentiated thyroid cancer (a type of thyroid cancer that no longer responds to radioiodine treatment) who are currently being monitored (Cohort 1)
- People newly diagnosed with medullary thyroid cancer that can be surgically removed, or people with medullary thyroid cancer that has spread and are being monitored, or people with advanced or spreading medullary thyroid cancer already under monitoring (Cohort 2)
- People with radioiodine-refractory differentiated thyroid cancer or medullary thyroid cancer who are either starting or already receiving systemic (whole-body) drug treatment (Cohort 3)
- People newly diagnosed with anaplastic thyroid cancer, which is a rare and fast-growing type of thyroid cancer (Cohort 4)
- People who have a stored tumour tissue sample available from a previous biopsy, or who are willing to have a new biopsy taken if needed
- People who are willing to follow standard monitoring and treatment as recommended by their medical team
- People who are willing and able to give consent for biological samples (such as blood or tissue) to be collected for research
Who may not be able to join:
- People who have another illness or condition that, in the treating doctor's opinion, would make it difficult to complete all the required sample collections
- People who have been diagnosed with another invasive cancer within the past 5 years (exceptions may apply for certain skin cancers or very early-stage cancers — confirm with trial site)
- People who are currently pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kate Newbold, Royal Marsden NHS Foundation Trust
Phone: 02000000000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary objective of the proposed study is to determine the sensitivity of detecting the presence of plasma ctDNA in patients with advanced and recurrent thyroid cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.